

Cetraria Islandica as a Pulmonary Cytoprotective and Supportive Herbal Remedy for Lung Complications Related to COVID-19

Salama M. El-Darier^{1*}, Amani W. Nasser²^{1, 2}Botany and Microbiology Department, Faculty of Science, Alexandria University, Alexandria, EgyptDOI: [10.36348/sijtem.2021.v04i10.001](https://doi.org/10.36348/sijtem.2021.v04i10.001)

| Received: 13.09.2021 | Accepted: 18.10.2021 | Published: 24.10.2021

*Corresponding author: Salama M. El-Darier

Abstract

At the end of 2019, COVID-19 (SARS-CoV-2) has become a global pandemic with severe acute respiratory syndrome. The virus started from Wuhan, China on 29 December 2019 and spread widely all over the world in a short period. The present review reports the activity of one striking lichen; *Cetraria islandica* (L.) Ach. as probable complementary effective treatment for symptoms associated with Covid-19, infection. Many potential treatments have been introduced, which are considered potent antiviral drugs and commonly reported as herbal or traditional and medicinal treatments. Currently, several studies confirmed that herbal medicine plays a major role in the prevention and treatment of many diseases also for the novel coronavirus. As well as, the post-COVID syndromes which have been detected in many people who've "recovered" from COVID-19 but still suffering from its pulmonary symptoms. In the light of findings reported in the present study, *C. islandica* supplements can add a significant role to protect lung from COVID-19 symptoms and post-COVID syndrome alongside with synthetic drugs or vaccines. Therefore, *C. islandica* supplements have the potential of being utilized as novel bio-resources for naturally occurring phytotherapies.

Keywords: COVID-19, Complementary medicine, Herbal medicine, *Cetraria islandica*, Pulmonary complaints.

Copyright © 2021 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

1. INTRODUCTION

In the future, the use of alternative plant-based molecules in the treatment of cancer, and finding new therapeutic agents with fewer side effects, both economically and because of the high side effects of existing treatments, is very important. The number of studies investigating the anticancer properties of plants is increasing day by day (El-Darier et al., 2018 and 2021a). An in vitro study on antimicrobial and anticancer potentiality of thyme and clove oils Rendiconti Lincei. Scienze Fisiche e Naturali 29:131–139 and El-Darier, S. M., Kamal, S. A., Marzouk, R. I & Nour, I. H. (2021). Anti-Proliferative Activity of *Launaea fragilis* (Asso) Pau and *Launaea nudicaulis* (L.) Hook.F. Extracts. Biomed J Sci & Tech Res 35(2)-2021). Plants considered as a treasure of miraculous compounds with abilities to cure diseases and make our immunity strong (Li et al., 2019) The importance of antiviral compounds produced from plants as a traditional use is based on their wisdom, faith, availability and positive results for generations for curing ailments or diseases. Although there have been relatively few studies seeking antiviral agents from this natural source, some studies have revealed an

unexpectedly frequent occurrence of antiviral activity in plants (Babich et al., 2020).

Lichens can produce secondary metabolites with important biological activities such as antioxidants, antibacterial and anti-inflammatory (Sahin et al., 2021). Lichen extracts, could be used as the basis of some pharmaceutical formulations due to pharmacological potential of their biological active compounds especially polysaccharide content (Patriche et al., 2019). Less than 100 out of 13,500 species have been investigated and polysaccharides are mainly of three different types: b-glucans, a-glucans, and galactomannans with a biological effect as antitumour, immunomodulation, antiviral, and memory-enhancing effects (Olafsdottir and Ingólfssdottir, 2001).

As well, with the global developments of COVID-19 the typical treatments must include home remedy, herbal medicine, chemical drugs, plasma therapy, and also, vaccines (Barati et al., 2020). The main objective of this paper is to review the capability of *C. islandica* herbal remedy for the treatment of the lung complains associated with COVID-19 infection.

2. CORONAVIRUS (COVID-19)

WHO (2020) used the term COVID-19 to refer to a coronavirus that affected the lower respiratory tract of patients with pneumonia in Wuhan, China. In addition, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a current reference name for COVID-19 virus. The virus belongs to the β -coronaviruses family which cause several symptoms related to the respiratory system. Since the beginning of the twenty-first century, three coronaviruses crossed the species barrier and causes deadly pneumonia in humans: severe acute respiratory syndrome coronavirus (SARS-CoV) (Drosten *et al.*, 2003), Middle-East respiratory syndrome coronavirus (MERS) (Zaki *et al.*, 2012), and SARS-CoV-2 (Huang *et al.*, 2020). Unlike (MERS) and (SARS), the transmission rate for COVID-19 is much higher due to the high rate of contagious and highly nonspecific symptoms of this disease (Gates, 2020).

The most thought-provoking observations that, the virus have no symptoms in some cases. While, when the virus does cause symptoms, there are common ones include fever, body ache, dry cough, fatigue, chills, headache, sore throat, loss of appetite, and loss of smell. The more interesting observation are the extreme symptoms in some cases like high fever, severe cough, and shortness of breath, which often indicates pneumonia (Huang *et al.*, 2020 and Tale *et al.*, 2020).

Several natural and synthetic drugs that have antiviral activity *in vitro* were considerably less effective when tested *in vivo* conditions. It became evident that transport of the drug to cells in the infected tissue is a major difficulty, especially when tissues become inflamed as a result of the viral infection (Visintini *et al.*, 2013). Since treatment of a virus infection is usually initiated when the symptoms are already obvious, introduction of a drug with antiviral activity at this stage is probably not sufficient to cure the infection if other elements such as lung, lymphocytes and connective tissues have been activated and proceed to cause damage to the virus-infected tissue. Antiviral drugs, therefore, should be used in combination with anti-inflammatory drugs to suppress both the virus and tissue effects (Perez, 2003).

Which make matters worse, the more apparent of people who've "recovered" from COVID-19 and go on to experience symptoms that linger well beyond testing negative for the virus. These individuals are sometimes referred to as "COVID long-haulers," and experts are searching for answers about this condition that's now being termed post-COVID syndrome (Tale *et al.*, 2020). Post-COVID syndrome (pneumonia pulmonary edema) can certainly impact quality of life. To overcome these prolonged pulmonary symptoms supplementary herbal medicines are effective as it's no matter for its use for long time which may be reaching

to six months after recovered from the virus (El-Darier *et al.*, 2021b).

3. LICHENS

More than 20,000 known species of lichens have been identified and inhabit diverse ecosystems ranging from arctic tundra to desert climates (Oboh and Ademosun, 2006). Ethnomedicines are a vast source of structural diversities and extensive bioactivities that can serve as a huge source of potential antiviral drugs. A significant number of plants serve as potential remedies to decrease the severity of illness caused by viruses (Jadhav *et al.*, 2012). Lichen is a stable, ecologically obligate, composite organism that emerges from an exhibiting fungus (the mycobiont) and one or more extracellularly located photoautotrophic unicellular or filamentous algal species (Hawksworth and Honegger, 1994). So that, there is a self-supporting mutualism between algae or cyanobacteria and the fungi as a beneficial symbiotic relationship.

It has been observed that the medical importance of the lichens has increased with secondary metabolites that they produce (Sahin *et al.*, 2019). Secondary metabolites have been shown to have anticancer (Emsen *et al.*, 2021), gastroprotective (de Castro Fonseca *et al.*, 2016), antinociceptive (Melo *et al.*, 2008), antibacterial (Gökalsın and Sesal, 2016), antifungal (Karabulut and Ozturk, 2015), antiviral (Sokolov *et al.*, 2012), antiprotozoal (Schmeda-Hirschmann *et al.*, 2008), and insecticidal (Emsen *et al.*, 2015) properties. Interestingly, it was found that lichens are effective in the treatment of bronchitis and tuberculosis diseases (Kim and Choc, 2007). So as to lichens may be considered as an easily accessible sources of natural drugs and possible food supplements after their safety evaluations (Turkez *et al.*, 2012). Their biological activities and chemical compositions have long been investigated for their antimicrobial (Candan *et al.*, 2007), antiviral (Fazio *et al.*, 2007) and anti-tumor effects (Rezanka and Dembitsky, 2006). From these purposes, Lichens are used in folk medicine for the treatment of diverse pathologies, from respiratory to digestive diseases, as they contain over 500 potentially bioactive compounds identified up-to-date.

Secondary metabolites are produced by the fungus alone and secreted onto the surface of lichen's hyphae either in amorphous forms or as crystals. If these substances are only found in lichens, they are called lichen substances (Öztürk *et al.*, 1999). One of the most specific lichen substances is lichenic acids, such as usnic acid, lobaric acid, lecanoric acid or salazinic acid, are among these compounds, with biopharmaceutical applications as antimicrobial, antioxidant and cytotoxic agents.

3.1 CETRARIA ISLANDICA (L.) ACH.

3.1.1 Morphology



Plate-1: Morphology of *Cetraria islandica*.

Cetraria islandica vary in colour from deep brown to grayish white and may grow to a height of 7 cm. It is the first lichen used as food by humans (HMPC, 2017).

3.1.2 Medicinal uses

Cetraria islandica has been used through the ages in traditional medicine in many countries. It was supposed to be effective in treatment of pulmonary tuberculosis, throat irritation, gastritis, dry cough, diabetes, hemorrhoids, bronchitis and dysentery. It is a cooling expectorant, soothes irritated tissue and controls vomiting. Traditionally, it is used mild inflammation of the oral and pharyngeal mucosa. It is also valued in dyspepsia and loss of appetite. It stimulates the secretion of saliva and gastric juices. *Cetraria islandica* is one of nature's most potent cough relievers; it is a well-known sore throat remedy and a fantastically in tackling all kinds of respiratory problems such as treatment of pulmonary tuberculosis. The lichen has valued folk remedy for lung diseases, kidney and bladder complaints as well as externally for poorly healed wounds (Bown, 2001).

Cetraria islandica neither has toxic effects nor do drug interactions by its use as a supplement remedy (Patrice *et al.*, 2019). Freysdóttir *et al.* (2008) suggested that the aqueous extract from *C. islandica* has an anti-inflammatory effect and protolichesterinic acid was found to be a potent inhibitor of the DNA polymerase activity of human immunodeficiency virus (HIV), with 50% inhibitory dose of 24 μ M. It is not cytotoxic with cultured mammalian cells (Güven *et al.*, 2018). Furthermore, Gulcin *et al.* (2002) study the antioxidant activity of *C. islandica* and obtained that the aqueous extract of *C. islandica* can be used as an easily accessible source of natural antioxidants as a possible food supplement or in pharmaceutical industry. The historical overview of the important medicinal uses of *C. islandica* indicates that there are specific chemical

Cetraria islandica (Iceland moss, Parmeliaceae) is lichen whose erect leaf like habit gives it the appearance of a moss, where its name comes (Plate 1).

constituents such as high proportions of polysaccharides lichenan and isolichenan, galactomannans, glucans and several secondary metabolites such as protolichesterinic acid and fumarprotocetraric acid, lichenolic acids and aliphatic lichen acid (Olafsdóttir and Ingólfssdóttir, 2001).

3.1.3 Active constituents

A. Polysaccharides

β -glucan lichenan

Isolichenan (a (1,3;1,4)-linked β -glucan) is present along with lichenan (Kramer *et al.*, 1995). The first polysaccharide fraction isolated from *C. islandica* was a mixture of lichenan and isolichenan in 1813 by Berzelius (Smith, 1921). The (1,3;1,4)- β -glucan lichenin is extractable with hot water from the fronds of *C. islandica*. The glucan is located in the cell walls of the mycobiont (Honegger and Haisch, 2001) and exhibited antiviral activity against numerous viruses of different taxonomic groups (TMV, PVY, TEV, PYX, TRV, CMV) (Stübler and Buchenauer, 1993).

McCarty and DiNicolantonio (2020) recently described the potential role of β glucan as a natural nutraceutical for boosting type 1 interferon response to RNA viruses such as influenza and coronavirus. Putative use of β -glucans in mitigating lung infections correlates with findings from our recent in vivo studies to address ARDS (Masterson *et al.*, 2019).

Galactomannans

Galactose and mannose were recognized early 1906 as a polysaccharide fractions extracted from *C. islandica* (Ulander *et al.*, 1906) but more detailed structural investigations on this group of lichen polysaccharides were mainly carried out over the past 15 years. These polysaccharides have a strong antiviral activity. As well as sulfate derivative, GE-3-S, prepared

by chlorosulfonic acid treatment of GE-3 has been shown to inhibit the replication of human immunodeficiency virus (HIV) in vitro. GE-3-S inhibited the cytopathic effect of HIV and suppressed HIV-antigen expression in Molt-4 cells without inhibiting HIV-reverse transcriptase. Sulfate derivatives of lichenan from *C. islandica* and PC-3 from *Parmelia caperata* were inactive against HIV as were the unsulfated counterparts (Hirabayashi *et al.*, 1989).

B. Lichen acids

Cetraria islandica contains large amounts of fumaroprotocetraric acid (2.6-11.5%) and protocetraric acid (0.2-0.3%) with strong antioxidant and bacteriostatic effects. Lichen acids and fumaric acid considered as immunomodulatory as they dominate the immune system and regulate the immune response. Isolated protolichesterinic acid was found to be a potent inhibitor of the DNA polymerase activity of human immunodeficiency virus-1 reverse transcriptase (HIV-1 RT), with 50% inhibitory dose of 24 μ M. It showed negligible cytotoxic activity with a variety of cultured mammalian cells (Pengsuparp *et al.*, 1995). Virus inhibition is more likely the result of suppressive effects on virus replication or cell-to-cell movement from initially occupied cells (Stübler and Buchenauer, 1996).

3. CONCLUSION

In the light of findings reported in the present study, *C. islandica* supplements can add a significant role to protect lung from COVID-19 symptoms and post-COVID syndrome alongside with synthetic drugs or vaccines. Therefore, *C. islandica* supplements have the potential of being utilized as novel bio-resources for naturally occurring phytotherapies.

4. RECOMMENDATIONS

Herbal tea of *C. islandica* was recommended as a demulcent for the symptomatic treatment of oral or pharyngeal irritation, lung complaints as well as associated dry cough (Herbal tea: 1.5 g of the comminuted herbal substance in 150 ml of boiling water as an herbal infusion or as a macerate 3 to 4 times daily). Enhancement of immunity system was acquired from 2 g of the *C. islandica* substance boiled in 100 ml water for 15 minutes.

5. REFERENCES

- Babich, O., Sukhikh, S., Prosekov, A., Asyakina, L., & Ivanova, S. (2020). Medicinal Plants to Strengthen Immunity during a Pandemic. *Pharmaceuticals*, 13, 313. Assessment report on *Cetraria islandica* (L.) Acharius s.l., thallus, Committee on Herbal Medicinal Products. *European Medicines Agency*, 2014.
- Barati, F., Pouresmaieli, M., Ekrami, E., Asghari, S., Ziarani, F. R., & Mamoudifard, M. (2020). Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review. *Biological Procedures Online*, 22(1), 1-17.
- Bown, D. (2001). Encyclopedia of herbs and their uses. Dorling Kindersley, London Committee on Herbal Medicinal Products (HMPC) Assessment (2017). Iceland moss, *Cetraria islandica* (L.) Acharius s.l., thallus, European Medicines Agency, Science Medicines Health, pp2.
- Candan, M., Yılmaz, M., Tay, T., Erdem, M., & Türk, A. Ö. (2007). Antimicrobial activity of extracts of the lichen *Parmelia sulcata* and its salazinic acid constituent. *Zeitschrift für Naturforschung C*, 62(7-8), 619-621.
- Committee on Herbal Medicinal Products (HMPC) Assessment. (2014). Report on *Cetraria islandica* (L.) Acharius s.l., thallus, European Medicines Agency, Science Medicines Health, pp34.
- de Castro Fonseca, J., de Oliveira, Y. S., Bezerra, B. P., Ellena, J., Honda, N. K., Silva, C. V., ... & Ayala, A. P. (2016). Diffraitaic acid: Crystalline structure and physicochemical characterization. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, 165, 26-32.
- Drosten, C., Günther, S., Preiser, W., Van Der Werf, S., Brodt, H. R., Becker, S., ... & Doerr, H. W. (2003). Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *New England journal of medicine*, 348(20), 1967-1976.
- El-Darier, S. M., El-Ahwany, A. M. D., Elkenany, E. T. & Abdeldaim, A. A. (2018). An in vitro study on antimicrobial and anticancer potentiality of thyme and clove oils *Rendiconti Lincei. Scienze Fisiche e Naturali* 29:131–139.
- El-Darier, S. M., Kamal, S. A., Marzouk, R. I & Nour, I. H. (2021a). Anti-Proliferative Activity of *Launaea fragilis* (Asso) Pau and *Launaea nudicaulis* (L.) Hook.F. Extracts. *Biomed J Sci & Tech Res* 35(2), 27492-96.
- El-Darier, S. M., Rashed, S. A., Fayez, A., Hassanein, S. S., Sharaby, M. R., Tawfik, N. M., Mansour, H & Adel, M. (2021b). Medicinal plant-derived compounds as potential phytotherapy for COVID-19: Future perspectives. *Journal of Pharmacognosy and Phytotherapy*, 13(3), 68-81
- Emsen, B., Sadi, G., Bostanci, A., Gursoy, N., Emsen, A., & Aslan, A. (2021). Evaluation of the biological activities of olivetoric acid, a lichen-derived molecule, in human hepatocellular carcinoma cells. *Rendiconti Lincei. Scienze Fisiche e Naturali*, 32(1), 135-148.
- Emsen, B., Yıldırım, E., & Aslan, A. (2015). Insecticidal activities of extracts of three lichen species on *Sitophilus granarius* (L.)(Coleoptera: Curculionidae).
- Fazio, A. T., Adler, M. T., Bertoni, M. D., Sepúlveda, C. S., Damonte, E. B., & Maier, M. S.

- (2007). Lichen secondary metabolites from the cultured lichen mycobionts of *Teloschistes chrysophthalmus* and *Ramalina celastri* and their antiviral activities. *Zeitschrift für Naturforschung C*, 62(7-8), 543-549.
- Freysdóttir, J., Omarsdóttir, S., Ingólfssdóttir, K., Víkingsson, A., & Ólafsdóttir, E. S. (2008). In vitro and in vivo immunomodulating effects of traditionally prepared extract and purified compounds from *Cetraria islandica*. *International immunopharmacology*, 8(3), 423-430.
 - Galun, M. (1988). CRC Handbook of Lichenology, 13, 729D751. Vol. 3. CRC Press, Boca Raton, Florida, 95D107.
 - Gates, B. (2020). Responding to Covid-19—a once-in-a-century pandemic? *N Engl J Med*. 382(18);1677–9.
 - Gerhard, M., & Price, R. M. (1938). Lehrbuch der biologischen Heilmittel. band II, Georg Thieme, Verlag, Leipzig, 1436.
 - Gessner, O., Orzechowski, G., & Mitteleuropa, A.V. (1974). 3rd ed. Carl Winter Universitätsverlag, Heidelberg.
 - Gökalsın, B., & Sesal, N.C. (2016). Lichen secondary metabolite evernic acid as potential quorum sensing inhibitor against *Pseudomonas aeruginosa*. *World J Microbiol Biotechnol* 32(9):150.
 - Grujičić, D., Stošić, I., Kosanić, M., Stanojković, T., Ranković, B., & Milošević-Djordjević, O. (2014). Evaluation of in vitro antioxidant, antimicrobial, genotoxic and anticancer activities of lichen *Cetraria islandica*. *Cytotechnology*, 66(5), 803-813.
 - Gülçin, İ., Oktay, M., Küfrevioğlu, Ö. İ., & Aslan, A. (2002). Determination of antioxidant activity of lichen *Cetraria islandica* (L) Ach. *Journal of ethnopharmacology*, 79(3), 325-329.
 - Hawksworth, D. L., & Honegger, R. (1994). The lichen thallus: a symbiotic phenotype of nutritionally specialized fungi and its response to gall producers. *Systematics association special volume*, 49, 77-77.
 - Hawksworth, D. L., & Honegger, R. (1994). The lichen thallus: a symbiotic phenotype of nutritionally specialized fungi and its response to gall producers. *Systematics association special volume*, 49, 77-77.
 - Hirabayashi, K., Iwata, S., ITO, M., Shigeta, S., Narui, T., Mori, T., & Shibata, S. (1989). Inhibitory effect of a lichen polysaccharide sulfate, GE-3-S, on the replication of human immunodeficiency virus (HIV) in vitro. *Chemical and pharmaceutical bulletin*, 37(9), 2410-2412.
 - Honegger, R., & Haisch, A. (2001). Immunocytochemical location of the (1→3)(1→4)-β-glucan lichenin in the lichen-forming ascomycete *Cetraria islandica* (Icelandic moss). *New phytologist*, 150(3), 739-746.
 - Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 395(10223):497–506.
 - Ingólfssdóttir K. (2000). Bioactive compounds from Iceland moss, in B.S. Paulsen (ed.). *Bioactive Carbohydrate Polymers*. Kluwer Academic Publishers, Chapter 3, 25-36.
 - Jadhav P., Kapoor N., Thomas B., Lal H., Kshirsagar N. (2012). Antiviral potential of selected Indian medicinal (ayurvedic) plants against Herpes Simplex Virus 1 and 2. *Research Letter*, Volume: 4, Issue: 12, P: 641-647.
 - Jaime, M. F. V., Redko, F., Muschietti, L. V., Campos, R. H., Martino, V. S., & Cavallaro, L. V. (2013). In vitro antiviral activity of plant extracts from Asteraceae medicinal plants. *Virology journal*, 10(1), 1-10.
 - Karabulut, G., & Ozturk, S. (2015). Antifungal activity of *Evernia prunastri*, *Parmelia sulcata*, *Pseudevernia furfuracea* var. *furfuracea*. *Pak J Bot*, 47(4):1575–1579.
 - Kim, M. S., & Cho, H. B. (2007). Melanogenesis inhibitory effects of methanolic extracts of *Umbilicaria esculenta* and *Usnea longissima*. *Journal of Microbiology*, 45(6), 578-582.
 - Krämer, P., Wincierz, U., Grübler, G., Tschakert, J., Voelter, W., & Mayer, H. (1995). Rational approach to fractionation, isolation, and characterization of polysaccharides from the lichen *Cetraria islandica*. *Arzneimittelforschung*, 45, 726–731.
 - Li, K., Ma, C., Li, H., Dev, S., He, J., & Qu, X. (2019). Medicinal value and potential therapeutic mechanisms of *Gynostemma pentaphyllum* (Thunb.) Makino and its derivatives: An overview. *Current topics in medicinal chemistry*, 19(31), 2855-2867.
 - Luo, H., Tang, Q. L., Shang, Y. X., Liang, S. B., Yang, M., Robinson, N., & Liu, J. P. (2020). Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. *Chinese journal of integrative medicine*, 26(4), 243-250.
 - Masterson, C. H., Murphy, E., Major, I., Gonzalez, H., O'Toole, D., McCarthy, S., ... & Rowan, N. (2019). Purified beta-glucan from the *Lentinus edodes* mushroom attenuates antibiotic resistant *Klebsiella pneumoniae*-induced pulmonary sepsis. In *A28. BACTERIAL AND VIRAL LUNG INFECTIONS AND PATHOGENESIS* (pp. A1222-A1222). American Thoracic Society.

- McCarty, M. F., & DiNicolantonio, J. J. (2020). Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus. *Progress in cardiovascular diseases*, 63(3), 383.
- Melo, M. G. D., Araujo, A. A. S., Rocha, C. P. L., Almeida, E. M. S. A., de Souza Siqueira, R., Bonjardim, L. R., & Quintans-Júnior, L. J. (2008). Purification, physicochemical properties, thermal analysis and antinociceptive effect of atranorin extracted from *Cladonia kalbii*. *Biological and Pharmaceutical Bulletin*, 31(10), 1977-1980.
- Murphy, E. J., Masterson, C., Rezoagli, E., O'Toole, D., Major, I., Stack, G. D., ... & Rowan, N. J. (2020). β -Glucan extracts from the same edible shiitake mushroom *Lentinus edodes* produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects—Implications for coronavirus disease (COVID-19) immunotherapies. *Science of the Total Environment*, 732, 139330.
- Oboh, G., Ademosun, A.O. (2006). Comparative studies on the ability of crude polyphenols from some nigerian citrus peels to prevent lipid peroxidation: in vitro. *Asian J Biochem*, 1; 169–177
- Olafsdottir, E.S., Ingólfssdottir, K. (2001). Polysaccharides from Lichens: Structural Characteristics and Biological Activity *Planta Med*, 67; 199–208.
- Öztürk, S., Arikan, N., Yilmaz, Ö., & Güvenç, S. (1999). Effect of usnic acid on mitotic index in root tips of *Allium cepa* L. *Lagascalia*, 21 (1), 47-52.
- Patriche, S., Ghinea, I., Adam, G., Gurau, G., Furdui, B., Dinica, R., - Rebegea, L., Lupoaie, M. (2019). Characterization of Bioactive Compounds from Romanian *Cetraria islandica* (L.) Ach. *REV.CHIM. (Bucharest)* 70(6), 2186-2191.
- Pengsuparp, T., Cai, L., Constant, H., Fong, H.H.S., Lin, L.Z., Kinghorn, A.D., Pezzuto J.M., Cordell, G.A., Ingólfssdóttir, K., Wagner, H., Hughes, S.H. (1995). Mechanistic evaluation of new plant-derived compounds that inhibit HIV-1 reverse transcriptase. *J Nat Prod*, 58(7); 1024-1031.
- Perez, G. (2003). Antiviral activity of compounds isolated from plants, *Pharmaceutical Biology*, 41(2), 107–157.
- Rezanka, T., Dembitsky, V.M. (2006). The colleflaccinosides, two chiral bianthraquinone glycosides with antitumor activity from the lichen *Collema flaccidum* collected in Israel and Russia. *Nat Prod Res*, 20; 969–980.
- Sahin, E., Dabagoglu, Psav, S., Avan, I., Candan, M., Sahinturk, V., & Koparal, A. (2019). Vulpinic acid, a lichen metabolite, emerges as a potential drug candidate in the therapy of oxidative stress-related diseases, such as atherosclerosis. *Hum Exp Toxicol*, 38(6); 675–684.
- Sahin, E., Psav, S. D., Avan, I., Candan, M., Sahinturk, V., & Koparal, A. T. (2021). Lichen-derived physodic acid exerts cytotoxic and anti-invasive effects in human lung cancer. *Rendiconti Lincei. Scienze Fisiche e Naturali*, 32; 511–520.
- Salama, M., El-Ahwany, A. M., Elkenany, E. T., & Abdeldaim, A. A. (2018). An in vitro study on antimicrobial and anticancer potentiality of thyme and clove oils. *Rendiconti Lincei. Scienze Fisiche e Naturali*, 29(1), 131-139.
- Salama, M., Rashed, S. A., Fayez, A., Hassanein, S. S., Sharaby, M. R., Tawfik, N. M., ... & Adel, M. (2021). Medicinal plant-derived compounds as potential phytotherapy for COVID-19: Future perspectives. *Journal of Pharmacognosy and Phytotherapy*, 13(3), 68-81.
- Schmeda-Hirschmann, G., Tapia, A., Lima, B., Pertino, M., Sortino, M., Zacchino, S., de Arias, A. R., & Feresin, G.E. (2008). A new antifungal and antiprotozoal depside from the Andean lichen *Protousnea poeppigii*. *Phytother Res*, 22(3); 349–355.
- Smith AL. Lichens. Cambridge University Press, 1921
- Sokolov, D.N., Zarubaev, V. V., Shtro, A. A., Polovinka, M.P., Luzina, O. A., Komarova, N.; Salakhutdinov, N. F., & Kiselev, O. I. (2012). Antiviral activity of (–)-and (+)-usnic acids and their derivatives against influenza virus A (H1N1) 2009. *Bioorg Med Chem Lett*, 22(23); 7060–7064.
- Stübler, D., & Buchenauer, H. (1993). Antiviral Properties of Lichenan (β {1–3,1–4}D-Glucan) in Tobacco. In: Fritig B., Legrand M. (eds) Mechanisms of Plant Defense Responses. Developments in Plant Pathology, 2. Springer, Dordrecht.
- Stübler, D., Buchenauer, H. (1996). Antiviral activity of the glucan lichenan (Poly- β { \rightarrow 3,1 \rightarrow 4}D anhydroglucose) 2. Studies on the mode of action. *J Phytopathol*, 144; 45-52.
- Tale, S., Ghosh, S., Meitei, S. P., Kolli, M., Garbhapu, A. K., & Pudi, S. (2020). Post-COVID-19 pneumonia pulmonary fibrosis. *QJM: An International Journal of Medicine*, 113(11), 837-838.
- The World Health Organization. (2020). Novel Coronavirus (2019-nCoV), Situation Report – 1, 21 January, 1-5.
- Türk, A. Ö., Yılmaz, M., Kıvanç, M., & Türk, H. (2003). The antimicrobial activity of extracts of the lichen *Cetraria aculeata* and its protolicheterinic acid constituent. *Zeitschrift für Naturforschung C*, 58(11-12), 850-854.
- Turkez, H., Aydin, E., & Aslan, A. (2012). *Xanthoria elegans* (Link)(lichen) extract

counteracts DNA damage and oxidative stress of mitomycin C in human lymphocytes. *Cytotechnology*, 64(6), 679-686.

- Ulander, A., Tollens, B. (1906). Untersuchungen über die Kohlenhydrate der Flechten. *Berichte der deutschen chemischen Gesellschaft*, 39; 401.
- WHO. (2020). Novel coronavirus – China. Jan 12, 2020. <http://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/>.
- WHO. Monographs. (2004). Selected Medicinal Plants, Volume 4. Lichen islandicus. World Health Organization, Geneva, 140-148.
- Zaki, A. M., Van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D., & Fouchier, R. A. (2012). Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *New England Journal of Medicine*, 367(19), 1814-1820.